A Prescription Under Scrutiny: How Clinical Evidence Reshaped the Way Physicians View Ciprofloxacin
Over the past five years, ciprofloxacin prescribing rates in the United States have declined considerably as updated clinical guidelines and emerging safety data have prompted physicians to reassess the drug's risk-benefit profile. This article examines the key forces behind that shift, from regulatory warnings to the rise of antibiotic stewardship programs, and explains what this change means for patients navigating their treatment options today.